(firstQuint)Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck.

 METHODOLOGY: The present study is a multicenter, open-label, non-controlled, phase II study in patients who are suffering from recurrent and/or metastatic Salivary Glands Carcinoma, who have progressed during the 6 months period before entering the study and who are eligible for nivolumab monotherapy.

 All eligible patients will receive nivolumab treatment for a maximum of 12 cycles of treatment.

 92 eligible patients will be dosed with nivolumab intravenously over 60 minutes ( 5 minutes) at 3 mg/kg every two weeks.

 Each 28-day dosing period will constitute a cycle.

.

 Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck@highlight

INDICATION: Patients with recurrent and/or metastatic salivary glands carcinoma who have progressed during the 6 months period before entering the study and who are eligible for nivolumab monotherapy.

